Interventional Enrolling by invitation
NCT06731842 on ClinicalTrials.gov
Molecular PET Imaging and Plasma Biomarkers in Alzheimer´s Disease and Other Neurodegenerative Diseases
- Sponsor: Karolinska Institute
- Enrollment: 100 (Estimated)
- Study start: 2022-05-15 (Actual)
- Primary completion: 2027-12-31 (Estimated)
- Study completion: 2027-12-31 (Estimated)
- Allocation: N/a
- InterventionModel: Single Group
- Masking: None
- PrimaryPurpose: Diagnostic
Brief Summary
Multi-modal PET tracer study with the aim of studying the time course of regional deposition of tau in brain of subjects with high risk of being carriers of autosomal dominant Alzheimer´s disease and sporadic early onset and late onset Alzheimer´s disease patient (EOAD, LOAD) in tertiary memory clinic cohort in relation to MRI brain changes, plasma biomarker levels and cognitive performance.
Conditions
- Alzheimer´s Disease
Intervention / Treatment
- Other: 18F-RO948
Primary Outcome Measures
-
PET measurement of regional tau spreading in brain during Alzheimer continuum
(3 years)
Anaysis of regional deposition of tau in brain
Countries
Sweden
Locations and Investigators
- Karolinska institutet NVS, Stockholm, Sweden
Study Officials
- Agneta K NORDBERG, MD PhD (Principal Investigator) — Karolinska Institutet